Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Bortezomib overcomes the negative impact of CXCR4 mutations on survival of Waldenstrom macroglobulinemia patients
Romanos Sklavenitis‐Pistofidis, Marzia Capelletti, Chia‐Jen Liu, et al.
Blood (2018) Vol. 132, Iss. 24, pp. 2608-2612
Open Access | Times Cited: 35

Showing 1-25 of 35 citing articles:

Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment Strategies
Steven P. Treon, Lian Xu, Maria Luisa Guerrera, et al.
Journal of Clinical Oncology (2020) Vol. 38, Iss. 11, pp. 1198-1208
Open Access | Times Cited: 142
CXCR4 mutation subtypes impact response and survival outcomes in patients with Waldenström macroglobulinaemia treated with ibrutinib
Jorge J. Castillo, Lian Xu, Joshua Gustine, et al.
British Journal of Haematology (2019) Vol. 187, Iss. 3, pp. 356-363
Open Access | Times Cited: 87
CXCR4 in Waldenström’s Macroglobulinema: chances and challenges
Lisa Kaiser, Zachary R. Hunter, Steven P. Treon, et al.
Leukemia (2020) Vol. 35, Iss. 2, pp. 333-345
Open Access | Times Cited: 75
Waldenström macroglobulinemia: 2021 update on diagnosis, risk stratification, and management
Morie A. Gertz
American Journal of Hematology (2020) Vol. 96, Iss. 2, pp. 258-269
Open Access | Times Cited: 71
Diagnosis and management of Waldenström macroglobulinaemia—A British Society for Haematology guideline
Guy Pratt, Dima El‐Sharkawi, Jaimal Kothari, et al.
British Journal of Haematology (2022) Vol. 197, Iss. 2, pp. 171-187
Closed Access | Times Cited: 39
Bortezomib-Dexamethasone, Rituximab, and Cyclophosphamide as First-Line Treatment for Waldenström's Macroglobulinemia: A Prospectively Randomized Trial of the European Consortium for Waldenström's Macroglobulinemia
Christian Buske, Meletios Α. Dimopoulos, Alexander Grunenberg, et al.
Journal of Clinical Oncology (2023) Vol. 41, Iss. 14, pp. 2607-2616
Closed Access | Times Cited: 26
Ixazomib, dexamethasone, and rituximab in treatment-naive patients with Waldenström macroglobulinemia: long-term follow-up
Jorge J. Castillo, Kirsten Meid, Catherine Flynn, et al.
Blood Advances (2020) Vol. 4, Iss. 16, pp. 3952-3959
Open Access | Times Cited: 44
Single-cell RNA sequencing defines distinct disease subtypes and reveals hypo-responsiveness to interferon in asymptomatic Waldenstrom’s Macroglobulinemia
Romanos Sklavenitis‐Pistofidis, Yoshinobu Konishi, Daniel Heilpern-Mallory, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access
Bortezomib, Rituximab and Dexamethasone Regimen (BDR) in Waldenström Macroglobulinaemia: A Retrospective Real‐World Analysis
Thomas Hueso, Grégory Lazarian, Paul Chauvet, et al.
eJHaem (2025) Vol. 6, Iss. 2
Open Access
CXCR4 mutations affect presentation and outcomes in patients with Waldenström macroglobulinemia: A systematic review
Jorge J. Castillo, David F. Moreno, Maria I. Arbelaez, et al.
Expert Review of Hematology (2019) Vol. 12, Iss. 10, pp. 873-881
Closed Access | Times Cited: 33
New developments in the diagnosis and characterization of Waldenström’s macroglobulinemia
Ramón García‐Sánz, Zachary R. Hunter, Stéphanie Poulain, et al.
Expert Review of Hematology (2023) Vol. 16, Iss. 11, pp. 835-847
Open Access | Times Cited: 10
Report of Consensus Panel 3 from the 12th International Workshop on Waldenström's Macroglobulinemia on the Management of Patients with High-Risk Disease.
Prashant Kapoor, Meletios Α. Dimopoulos, Stephen M. Ansell, et al.
Seminars in Hematology (2025)
Closed Access
Efficacy and safety of bendamustine, rituximab and bortezomib treatment in relapsed/refractory Waldenstrom Macroglobulinaemia: results of phase 2 single‐arm FIL‐BRB trial
Giulia Benevolo, Daniela Drandi, Nicoletta Villivà, et al.
British Journal of Haematology (2024)
Closed Access | Times Cited: 2
Current approach to Waldenström macroglobulinemia
Prashant Kapoor, S. Vincent Rajkumar
Blood Reviews (2023) Vol. 62, pp. 101129-101129
Closed Access | Times Cited: 6
Immunoglobulin M Paraproteinaemias
Louis‐Pierre Girard, Cinnie Yentia Soekojo, Melissa Ooi, et al.
Cancers (2020) Vol. 12, Iss. 6, pp. 1688-1688
Open Access | Times Cited: 16
CXCR4 mutational status does not impact outcomes in patients with Waldenström macroglobulinemia treated with proteasome inhibitors
Jorge J. Castillo, Joshua Gustine, Kirsten Meid, et al.
American Journal of Hematology (2020) Vol. 95, Iss. 4
Open Access | Times Cited: 15
Treatment paradigm in Waldenström macroglobulinemia: frontline therapy and beyond
Saurabh Zanwar, Jithma P. Abeykoon
Therapeutic Advances in Hematology (2022) Vol. 13
Open Access | Times Cited: 8
SOHO State of the Art Updates and Next Questions: Targeted therapies and emerging novel treatment approaches for Waldenström Macroglobulinemia
David Sermer, Shayna Sarosiek, Andrew R. Branagan, et al.
Clinical Lymphoma Myeloma & Leukemia (2022) Vol. 22, Iss. 8, pp. 547-556
Open Access | Times Cited: 7
Diagnostic value of bone marrow core biopsy patterns in lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia and description of its mutational profiles by targeted NGS
Julia García-Reyero, Nerea Martı́nez, Sonia González de Villambrosía, et al.
Journal of Clinical Pathology (2020) Vol. 73, Iss. 9, pp. 571-577
Closed Access | Times Cited: 10
Combining Ixazomib With Subcutaneous Rituximab and Dexamethasone in Relapsed or Refractory Waldenström's Macroglobulinemia: Final Analysis of the Phase I/II HOVON124/ECWM-R2 Study
Marie José Kersten, Karima Amaador, Monique C. Minnema, et al.
Journal of Clinical Oncology (2021) Vol. 40, Iss. 1, pp. 40-51
Open Access | Times Cited: 9
Zanubrutinib in Treating Waldenström Macroglobulinemia, the Last Shall Be the First
Anagha Deshpande, Javier Muñoz
Therapeutics and Clinical Risk Management (2022) Vol. Volume 18, pp. 657-668
Open Access | Times Cited: 6
Deepening of response after completing rituximab‐containing therapy in patients with Waldenstrom macroglobulinemia
Jorge J. Castillo, Joshua Gustine, Andrew Keezer, et al.
American Journal of Hematology (2019) Vol. 95, Iss. 4, pp. 372-378
Open Access | Times Cited: 7
<p>Good Profile of Efficacy/Tolerance of Bortezomib or Idelalisib in Waldenström Macroglobulinemia Associated with Acquired Von Willebrand Syndrome</p>
Mario Ojeda‐Uribe, Valérie Rimelen, Cathérine Marzullo
Journal of Blood Medicine (2020) Vol. Volume 11, pp. 67-72
Open Access | Times Cited: 7
Ibrutinib in relapsed/refractory patients with Waldenström macroglobulinemia: a real-life, retrospective study on behalf of the “RTL” (regional Tuscan lymphoma network)
Emanuele Cencini, Ilaria Romano, Francesco Ghio, et al.
Annals of Hematology (2023) Vol. 102, Iss. 4, pp. 841-849
Closed Access | Times Cited: 2
How to Sequence Therapies in Waldenström Macroglobulinemia
Shayna Sarosiek, Steven P. Treon, Jorge J. Castillo
Current Treatment Options in Oncology (2021) Vol. 22, Iss. 10
Closed Access | Times Cited: 5
Page 1 - Next Page

Scroll to top